Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
The Biopharmaceutical Contract Manufacturing Market to Hit $38.07 Billion by 2029, Revenue to Double in the Next 6 Years – Arizton
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...
The Pharmaceutical R&D Outsourcing Market on Track for $150 Billion Milestone, North America Takes the Spotlight – Arizton
Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...